BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

Lilly’s Retatrutide Delivers 20.8% Weight Loss in Phase III Obesity and Type 2 Diabetes Trial

In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half...

October 01, 2026 | News

China Approves Jaypirca Across All Lines of Therapy for CLL/SLL

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

September 30, 2026 | News

Link Cell Therapies Begins Phase I Trial of Logic-Gated CAR-T Therapy for Kidney Cancer

LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD ...

September 30, 2026 | News

Hengrui Pharma Inks $2.6B Licensing Deal With Novo Nordisk for Oral GLP-1/GIP Therapy

HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total pot...

September 30, 2026 | News

iRegene Advances Off-the-Shelf Retinal Cell Therapy Into Clinical Trials in US and China

Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. iReg...

September 30, 2026 | News

Leo Cancer Care Advances Upright Radiation Therapy Experience for Children

Leo Cancer Care has announced plans to further invest in the treatment experience for children undergoing radiation therapy. Following the world's fi...

September 29, 2026 | News

Innovent Expands Global Phase III IBI363 Trial to Non-Squamous NSCLC

Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization...

September 29, 2026 | News

Akeso Enrols First Patient in Global Phase III Cadonilimab Trial for Advanced Gastric Cancer

Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating ...

September 29, 2026 | News

Lundbeck Relocates US Headquarters to Greater Boston, Establishes Global Innovation Hub

The new hub in Greater Boston will bring Lundbeck closer to one of the world's leading life sciences ecosystems, strengthening access to science, talent ...

September 28, 2026 | News

Earendil Labs, Genentech Ink $1.5B+ Deal to Develop AI-Driven Bispecific Antibodies

Earendil Labs, an AI-powered biotechnology company advancing next-generation biologics, today announced a research collaboration with Genentech, a member o...

September 25, 2026 | News

Sanyou Bio, NovoCodex Join Forces to Advance Next-Generation ADC Therapeutics

Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") and NovoCodex Biopharmaceuticals Co., Ltd. ("NovoCodex") jointly announced that the two companies have f...

September 25, 2026 | News

Turbine, Daiichi Sankyo Expand Virtual Biology Collaboration to Accelerate ADC Discovery

Turbine, a leading virtual biology company, announced the expansion of its collaboration with Daiichi Sankyo following the successful completio...

September 25, 2026 | News

Bio-Techne Shareholders Approve Acquisition by Merck KGaA

Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne ...

September 25, 2026 | News

European Commission Approves First-in-Class Obicetrapib for LDL-C Reduction

- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability...

September 25, 2026 | News

Stay Connected